首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer
【2h】

Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer

机译:导管原位癌成分的存在和数量对浸润性乳腺癌预后的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction: The role of ductal carcinoma in situ (DCIS) component on the outcome of invasive breast cancer is not yet completely clear. Our study aims to assess the impact of the presence and quantity of DCIS component on the outcome of patients operated for invasive breast cancer. Materials and methods: We collected retrospective data about patients operated at their breast for invasive cancer between 2007 and 2012, focusing on the presence of DCIS component. Then, we divided patients into four groups based on the quantity of DCIS component as follows: not found (group A), minimal (group B, <25%), extensive (group C, 25-75%), and prevalent (group D, >75%). We further defined “extensive intraductal component” (EIC) groups C and D together. Results: DCIS component was associated with young age, familial history of breast cancer and worse biological characteristics, including high grading, higher prevalence of Her2/Neu overexpression, hormone receptors negativity, comedo-like necrosis and multifocality/multicentricity. Despite the unfavorable prognostic factors, invasive cancers associated with EIC were frequently treated with radical surgery and resulted to have long disease-free survival and low local recurrence rate. In patients with DCIS component (groups B, C, and D) the extension of this component resulted indirectly correlated with local recurrence rate, tumor lymphovascular invasion, and lymphnode extracapsular invasion. The highest prevalence of local recurrences was found in group B, which tended to be less frequently treated with radical surgery than group D (P<0.05) and C (P=n.s.). Conclusions: Different clinical and tumor features among invasive breast cancer with and without DCIS component indicate that they are distinct entities probably originating by different pathways that deserve to be studied. Furthermore, the controversial results about the management of cancer with minimal intraductal component require further studies in order to reduce local recurrence.
机译:简介:导管原位癌(DCIS)成分在浸润性乳腺癌预后中的作用尚不完全清楚。我们的研究旨在评估DCIS成分的存在和数量对浸润性乳腺癌手术患者结局的影响。材料和方法:我们收集了2007年至2012年间乳腺癌浸润癌手术患者的回顾性数据,重点是DCIS成分的存在。然后,我们根据DCIS成分的数量将患者分为四组:未发现(A组),极少(B组,<25%),广泛(C组,25-75%)和普遍(组) D,> 75%)。我们进一步定义了“广泛的导管内成分”(EIC)组C和D。结果:DCIS成分与年龄,乳腺癌家族史和较差的生物学特征有关,包括高等级,Her2 / Neu过表达的较高患病率,激素受体阴性,粉刺样坏死和多焦点/多中心性。尽管预后因素不利,但与EIC相关的浸润性癌仍经常接受根治性手术治疗,结果无病生存期长且局部复发率低。在具有DCIS成分的患者(B,C和D组)中,该成分的扩展导致与局部复发率,肿瘤淋巴血管浸润和淋巴结囊外浸润间接相关。 B组的局部复发率最高,与D组(P <0.05)和C组(P = n.s。)相比,根治性手术的发生率较低。结论:具有和不具有DCIS成分的浸润性乳腺癌之间的临床和肿瘤特征不同,表明它们是不同的实体,可能源自不同的途径,值得研究。此外,关于以最小的导管内成分治疗癌症的争议性结果需要进一步研究,以减少局部复发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号